Real-world drug utilisation of nintedanib and pirfenidone for interstitial lung disease in Singapore

Antifibrotic therapies such as nintedanib and pirfenidone have transformed interstitial lung disease (ILD) treatment, representing a significant advancement in managing progressive fibrosing conditions. While these agents are used across Asia, their use in Southeast Asia, for example in Singapore, Malaysia or Indonesia, remains significantly under-represented in literature. To address these knowledge gaps in real-world use of antifibrotics among Southeast Asian population, we conducted a retrospective drug use evaluation at the ILD subspecialty service in Tan Tock Seng Hospital in Singapore from January 2016 to October 2024, with the aim to evaluate the usage patterns and clinical outcomes of nintedanib and pirfenidone in patients with ILD.